FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Senior Research Scientist, Dr. Chuo Fang M.D., Ph.D., delivered a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting that took place in San Diego May 7-10, 2025. The SID Annual Meeting provides a premier forum for skin biology research and education for researchers to share transformative scientific discoveries and medical innovations that improve human health.
The poster presentation entitled "Immunomodulatory Potential of Human Dermal Fibroblast Spheroids in Psoriasis Therapy " was presented as a part of a poster session on Friday May 9, 2025. The poster highlighted FibroBiologics’ human dermal fibroblast (HDF) spheroids potential to reduce psoriasis severity in preclinical models, and offer a scalable, cell-based therapy with durable effects. A PDF version of the poster can be viewed here.
"Presenting our work at the Society for Investigative Dermatology Annual Meeting highlights our continued commitment to advancing innovative, cell-based treatments for chronic inflammatory diseases, " said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "Psoriasis remains a challenging chronic disease with limited long-term treatment options, and our IND-enabling preclinical data demonstrate that our fibroblast-based candidate may potentially offer a durable, therapeutic option with a unique immunomodulatory mechanism, and enable a sustained remission, reduced relapse, and a significantly lower adverse side effects profile.”
For more information, please visit FibroBiologics ' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements " as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential and capabilities of human dermal fibroblast (HDF) spheroids fibroblasts. These forward-looking statements are based on FibroBiologics ' management 's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates, " "projected, " "expects, " "anticipates, " "forecasts, " "plans, " "intends, " "believes, " "seeks, " "may, " "will, " "should, " "future, " "propose " and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics ' management 's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors " and elsewhere in FibroBiologics ' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC 's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) risks related to FibroBiologics ' liquidity and its ability to maintain capital resources sufficient to conduct its business, and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
© 2025 GlobeNewswire, Inc. All Rights Reserved.
